EyePoint Pharmaceuticals (STU:PV3) Interest Expense : €-1.16 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is EyePoint Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. EyePoint Pharmaceuticals's interest expense for the three months ended in Dec. 2023 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.16 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. EyePoint Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was € -15.00 Mil. EyePoint Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was € 0.00 Mil. GuruFocus does not calculate EyePoint Pharmaceuticals's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

EyePoint Pharmaceuticals Interest Expense Historical Data

The historical data trend for EyePoint Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Interest Expense Chart

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-5.56

-5.97

-4.87

-3.01

-1.14

EyePoint Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.74	-0.76	-0.40	-	-

EyePoint Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.16 Mil.

EyePoint Pharmaceuticals (STU:PV3) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

EyePoint Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was €0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was €-15.00 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was €4.50 Mil.

EyePoint Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

GuruFocus does not calculate EyePoint Pharmaceuticals's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

EyePoint Pharmaceuticals (STU:PV3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

EYPT:USA PV3B:Germany

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3) Headlines

No Headlines